Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in Princeton, New Jersey and currently employs 107 full-time employees. The company went IPO on 2018-09-21. The firm is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Follow-Up Questions
Who is the CEO of Y-mAbs Therapeutics Inc?
Mr. Michael Rossi is the President of Y-mAbs Therapeutics Inc, joining the firm since 2023.
What is the price performance of YMAB stock?
The current price of YMAB is $8.61, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Y-mAbs Therapeutics Inc?
Y-mAbs Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Y-mAbs Therapeutics Inc market cap?
Y-mAbs Therapeutics Inc's current market cap is $391.2M
Is Y-mAbs Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 12 analysts have made analyst ratings for Y-mAbs Therapeutics Inc, including 0 strong buy, 0 buy, 13 hold, 1 sell, and 0 strong sell
